EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Unveiling the Role of Protein Posttranslational Modifications in Glioma Prognosis

Zhipeng Jiang, Hanxue Huang, Youwei Guo, Zihan Wang, Hailong Huang, Wen Yin, Haoxuan Huang, Lei Wang, Weidong Liu, Xingjun Jiang iD, Caiping Ren

CNS Neuroscience & Therapeutics · 2025

DOI: 10.1111/cns.70330 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2025. Verfasst von Zhipeng Jiang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China. Hauptthemen laut MEDLINE: Glioma, Protein Processing, Post-Translational, Brain Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Hunan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Gliomas represent the most aggressive malignancies of the central nervous system, with posttranslational modifications (PTMs) emerging as critical regulators of oncogenic processes through dynamic protein functional modulation. Despite their established role in tumor biology, the systematic characterization of PTM‐mediated molecular mechanisms driving glioma progression remains unexplored. This study aims to uncover the molecular mechanisms of glioma, with a focus on the role of PTMs.

Methods

We analyzed the PTM pathway to classify glioma patients into distinct clusters. Comprehensive analyses compared intercluster differences in clinical outcomes, mutational landscapes, and immune microenvironment profiles. Differentially expressed genes (DEGs) were identified to construct a robust prognostic prediction model with machine learning approaches. Among the genes included in the model, TOM1L1 (Target of Myb1 Like 1 Membrane Trafficking Protein) was selected for in vitro experimental validation to assess its role in glioma progression.

Results

PTMs were found to influence glioma prognosis significantly. Dysregulation in specific pathways, such as glutathionylation and citrullination, was correlated with more aggressive clinical features. The prognostic model, comprising DEGs such as TOM1L1 , demonstrated high predictive accuracy (c‐index = 0.867)—the scores derived from the model strongly correlated with glioma progression indicators. In vitro experiments revealed that TOM1L1 facilitates malignant progression by modulating PTM pathways, confirming its functional role in glioma.

Conclusion

Our study establishes the first comprehensive PTM atlas in gliomas, revealing subtype‐specific modification patterns with clinical and therapeutic implications. TOM1L1 emerges as a promising prognostic biomarker and a potential therapeutic intervention target. Targeting PTM pathways may offer novel strategies for glioma treatment, enhancing patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliomaProtein Processing, Post-TranslationalBrain NeoplasmsHumansPrognosisMaleFemaleCell Line, Tumor

Stichwörter der Autor:innen

TOM1L1gliomamultiomics analysisposttranslational modificationprognostic signature

Autor:innen und Institutionen

  • Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China.
  • Cancer Research Institute, Xiangya School of Basic Medical Science, Central South University, Changsha, Hunan, P.R. China.
  • National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China.
  • Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, and National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, P.R. China.
  • Institute of Clinical Pharmacology, Engineering Research Center for Applied Technology of Pharmacogenomics of Ministry of Education, Central South University, Changsha, P.R. China.
  • The NHC Key Laboratory of Carcinogenesis and the Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Central South University, Changsha, Hunan, P.R. China.

ORCID-Profile: Xingjun Jiang

Förderung

  • Natural Science Foundation of Hunan Province

Zitieren

APA

Jiang, Z., Huang, H., Guo, Y., Wang, Z., Huang, H., Yin, W., Huang, H., Wang, L., Liu, W., Jiang, X., & Ren, C. (2025). Unveiling the Role of Protein Posttranslational Modifications in Glioma Prognosis. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.70330

Vancouver

Jiang Z, Huang H, Guo Y, Wang Z, Huang H, Yin W, et al. Unveiling the Role of Protein Posttranslational Modifications in Glioma Prognosis. CNS Neuroscience & Therapeutics. 2025. doi:10.1111/cns.70330

BibTeX
@article{Jiang2025,
  author = {Jiang, Zhipeng and Huang, Hanxue and Guo, Youwei and Wang, Zihan and Huang, Hailong and Yin, Wen and Huang, Haoxuan and Wang, Lei and Liu, Weidong and Jiang, Xingjun and Ren, Caiping},
  title = {Unveiling the Role of Protein Posttranslational Modifications in Glioma Prognosis},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2025},
  doi = {10.1111/cns.70330}
}
Kostenlos starten →